MATP6-A Antibody

What is MT-ATP6 and why is it important in mitochondrial research?

MT-ATP6 (Mitochondrially Encoded ATP Synthase 6) is a critical component of mitochondrial ATP synthase (Complex V) that plays a key role in the proton channel and is directly involved in ATP production. This protein is encoded by the mitochondrial genome and functions as a key component of the proton channel in the F0 domain of ATP synthase. MT-ATP6 is essential for the translocation of protons across the mitochondrial membrane during ATP synthesis . Research on MT-ATP6 is particularly valuable because mutations in this gene are associated with several mitochondrial diseases including Leigh syndrome, NARP (Neurogenic Ataxia and Retinitis Pigmentosa), leukodystrophy, renal disease, and myoclonic epilepsy with cerebellar ataxia . Understanding MT-ATP6 structure and function provides critical insights into mitochondrial bioenergetics and disease mechanisms.

What types of MT-ATP6 antibodies are available for research applications?

Several types of MT-ATP6 antibodies are available for research applications, including:

• Host species variation: Primarily rabbit and goat polyclonal antibodies

• Target region specificity: Antibodies targeting different regions such as:

  • Internal region (e.g., ABIN2613453)

  • C-terminal region (e.g., ab190287)

  • Specific amino acid sequences (e.g., PTSKYLINNR LITTQ)

• Conjugation status:

  • Unconjugated antibodies for standard applications

  • Fluorophore-conjugated antibodies (e.g., Alexa Fluor 647, Alexa Fluor 750) for fluorescence-based applications

Selection should be based on specific experimental requirements, target species, and intended applications such as Western blotting, ELISA, immunohistochemistry, or immunofluorescence.

What are the standard applications for MT-ATP6 antibodies in mitochondrial research?

MT-ATP6 antibodies are utilized in several key applications in mitochondrial research:

These applications are instrumental in characterizing MT-ATP6 expression, localization, and function in normal and pathological conditions.

How can researchers optimize protocols for detecting MT-ATP6 in Blue Native PAGE experiments?

Blue Native PAGE (BN-PAGE) is crucial for studying ATP synthase assembly states and has been particularly valuable in analyzing MT-ATP6 mutations. Based on published methodologies:

• Sample preparation optimization:

  • Use digitonin (4-8 g/g protein) for gentle solubilization of mitochondrial membranes to preserve complex V integrity

  • Alternatively, lauryl maltoside can be used when studying F1 subcomplexes formation

  • Include protease inhibitors to prevent degradation during preparation

• Electrophoresis conditions:

  • Use gradient gels (typically 3-12% or 4-16%) for optimal resolution

  • Run at 4°C to maintain complex stability

  • Include Coomassie blue G-250 in the cathode buffer during initial run

• Detection strategies:

  • For detecting assembly defects, transfer to PVDF membrane and probe with anti-ATP5A (F1 subunit) alongside MT-ATP6 antibodies

  • This approach effectively reveals accumulation of F1 subcomplexes (x, y, and z) that occur when MT-ATP6 mutations disrupt complex assembly

• Complementary approaches:

  • Follow with second-dimension SDS-PAGE (2D-BNGE) to separate individual complex components

  • This technique has been successfully used to confirm incorporation of residual MT-ATP6 protein into fully assembled complex V

When analyzing patient samples with MT-ATP6 mutations, researchers have observed characteristic patterns including reduced levels of fully assembled complex V and accumulation of F1 subcomplexes, providing important functional insights into pathogenic mechanisms.

What are the methodological considerations when assessing MT-ATP6 protein stability in mutant models?

Assessing MT-ATP6 stability in disease models requires specialized approaches due to the protein's hydrophobicity and mitochondrial localization:

• Pulse-chase analysis has proven effective for measuring MT-ATP6 stability:

  • Label mitochondrial translation products with [35S]-methionine

  • Monitor decay of labeled proteins over time (e.g., 120-minute chase)

  • Quantify the percentage of newly synthesized MT-ATP6 remaining

  • Compare between wild-type and mutant samples

• Quantification methods:

  • For accurate comparison, normalize MT-ATP6 levels to loading controls (e.g., VDAC/porin)

  • Use densitometry software for precise quantification

  • Present data as percentage of remaining protein compared to the initial time point

• Example findings from published research:

  • In wild-type samples, approximately 50% of newly synthesized Atp6 remains after 120 minutes

  • In atp23 null mutants (deficient in Atp6 processing), only about 20% remains

  • In revertant strains with compensatory mutations, ~45% remains

• Complementary stability assessments:

  • Western blot analysis from steady-state samples

  • Comparison of MT-ATP6 protein levels across different tissues in heteroplasmic models

  • Correlation of protein stability with heteroplasmy levels

These methods have revealed that MT-ATP6 mutations can significantly impact protein stability, with truncating mutations typically showing more severe stability defects than missense mutations.

How should researchers design experiments to correlate MT-ATP6 heteroplasmy levels with protein expression and function?

Designing experiments to correlate MT-ATP6 heteroplasmy with protein function requires a multifaceted approach:

• Heteroplasmy quantification:

  • Use next-generation sequencing or quantitative PCR methods for precise measurement

  • Sample multiple tissues as heteroplasmy can vary significantly between tissue types

  • For patient-derived samples, collect data from blood, urinary epithelial cells, fibroblasts, and when available, skeletal muscle

• Protein expression analysis:

  • Perform Western blot with MT-ATP6 antibodies across tissues with varying heteroplasmy

  • Quantify protein levels relative to mitochondrial mass markers (e.g., VDAC/porin)

  • Create calibration curves correlating heteroplasmy percentage with protein abundance

• Functional assessments:

  • Measure ATP synthesis rates in isolated mitochondria or permeabilized cells

  • Assess mitochondrial membrane potential (often increased in MT-ATP6 mutations)

  • Evaluate ATP hydrolysis capacity (typically preserved despite synthesis defects)

• Integrative analysis:

  • Generate scatter plots comparing heteroplasmy levels with functional parameters

  • Calculate correlation coefficients to quantify relationships

  • Consider tissue-specific thresholds for biochemical defects

• Experimental models:

  • Transmitochondrial cybrid cells with controlled heteroplasmy levels

  • Patient-derived fibroblasts from individuals with varying mutation loads

  • Tissue samples from patients spanning different clinical severities

What are the common challenges in detecting MT-ATP6 by Western blotting and how can they be overcome?

Detecting MT-ATP6 by Western blotting presents several technical challenges due to its properties as a small, hydrophobic mitochondrial membrane protein:

• Sample preparation challenges and solutions:

  • Challenge: Incomplete solubilization

  • Solution: Use stronger detergents (1-2% SDS or 1% Triton X-100) for sample preparation; heat samples at 70°C rather than boiling to prevent aggregation

• Gel system optimization:

  • Challenge: Poor resolution of small hydrophobic proteins

  • Solution: Use Tricine-SDS-PAGE or 12-15% acrylamide gels optimized for lower molecular weight proteins; Bis-Tris gel systems (NuPAGE 4-12%) have shown good results

• Transfer efficiency problems:

  • Challenge: Inefficient transfer of hydrophobic proteins

  • Solution: Use PVDF membranes (rather than nitrocellulose); add 20% methanol to transfer buffer; consider semi-dry transfer systems or longer wet transfer times (overnight at lower voltage)

• Antibody selection considerations:

  • Challenge: Variable antibody performance

  • Solution: Test multiple antibodies targeting different epitopes; C-terminal antibodies often perform better for intact protein detection, while internal region antibodies may be preferable for detecting truncated variants

• Detection sensitivity issues:

  • Challenge: Low abundance in some samples

  • Solution: Use enhanced chemiluminescence substrates; consider signal amplification systems; load higher amounts of mitochondrial proteins (50-100 μg)

• Quantification standardization:

  • Challenge: Variable loading control performance

  • Solution: Use mitochondrial-specific loading controls (VDAC/porin) rather than general housekeeping proteins; normalize to mitochondrial mass markers

Researchers have successfully detected MT-ATP6 at approximately 20-25 kDa using antibodies like ab190287 (Abcam) or A02081 (Boster Bio) at dilutions of 1:500-1:1000 . Optimal results have been achieved with mitochondrial-enriched fractions rather than whole cell lysates.

How can researchers address variability in MT-ATP6 antibody performance across different experimental systems?

Variability in MT-ATP6 antibody performance can significantly impact experimental results. Here are methodological approaches to address this challenge:

• Comprehensive antibody validation strategy:

  • Validate each antibody lot with positive controls (isolated mitochondria from relevant species)

  • Include negative controls (mtDNA-depleted ρ0 cells or CRISPR-edited cells)

  • Test antibody performance in multiple applications before full experimental deployment

• Cross-antibody comparison methodology:

  • Run parallel experiments with multiple antibodies targeting different epitopes

  • Compare antibodies raised in different host species (rabbit vs. goat)

  • Create a performance matrix scoring each antibody across applications

• Species-specific considerations:

  • Verify cross-reactivity claims experimentally rather than relying solely on manufacturer data

  • For evolutionarily conserved regions, check sequence homology of the immunogen peptide

  • Consider preparing species-specific custom antibodies for specialized model systems

• Application-specific optimization:

  Application	Optimization Strategy
  Western blot	Optimize blocking conditions (5% milk vs. BSA); test multiple secondary antibodies
  IHC/IF	Test multiple antigen retrieval methods; optimize antibody concentration
  IP	Pre-clear lysates; test different binding conditions and wash stringency

• Data integration approach:

  • Combine antibody-based detection with complementary techniques (e.g., mass spectrometry)

  • Correlate protein detection with functional assays

  • Use genetic models with controlled expression for calibration

Researchers studying MT-ATP6 mutations have successfully addressed variability by using multiple detection methods in parallel and correlating antibody-based results with functional measurements of ATP synthase activity .

What strategies help overcome challenges in detecting truncated MT-ATP6 proteins resulting from pathogenic mutations?

Detecting truncated MT-ATP6 proteins presents unique challenges that require specialized approaches:

• Epitope-specific antibody selection:

  • For detecting N-terminal fragments, use antibodies targeting the internal region or N-terminus

  • For analyzing retained protein segments in frameshift mutations, map antibody binding sites relative to the mutation position

  • Consider custom antibodies raised against predicted truncated sequences

• Gel system modifications:

  • Use higher percentage gels (15-20%) to resolve small fragments

  • Consider gradient gels to simultaneously capture full-length and truncated proteins

  • Use Tricine-SDS-PAGE systems specifically optimized for low molecular weight proteins

• Enhanced detection methods:

  • Employ immunoprecipitation to concentrate low-abundance truncated proteins before Western blotting

  • Use high-sensitivity fluorescent secondary antibodies

  • Consider enhanced chemiluminescence substrates with extended exposure times

• Complementary analytical approaches:

  • Analyze mitochondrial translation products via [35S]-methionine labeling to detect shortened translation products

  • Use 2D-BN-PAGE to identify altered migration patterns of subcomplexes

  • Apply targeted mass spectrometry approaches to identify truncated peptides

• Validation in experimental models:

  • Generate cellular models expressing known truncation mutations

  • Use these as positive controls for antibody validation

  • Compare antibody performance against multiple truncation variants

Research on truncating MT-ATP6 mutations (m.8782G>A; p.Gly86* and m.8618dup; p.Thr33Hisfs*32) has demonstrated that combining Blue Native PAGE with standard SDS-PAGE provides the most comprehensive analysis, revealing both the presence of truncated proteins and their impact on complex V assembly . These approaches have shown that even with heteroplasmy levels of 27-71%, antibody detection of MT-ATP6 truncations is achievable when optimized methods are employed.

How can MT-ATP6 antibodies be utilized to characterize Complex V defects in patient samples?

MT-ATP6 antibodies are instrumental in characterizing Complex V defects in patient samples through multiple complementary approaches:

• Multi-level analysis strategy:

  • Protein level assessment: Quantify MT-ATP6 steady-state levels via Western blot

  • Complex assembly analysis: Use Blue Native PAGE to evaluate ATP synthase assembly state

  • Subcomplex characterization: Detect accumulation of F1 subcomplexes (x, y, and z) using anti-ATP5A alongside MT-ATP6 antibodies

• Tissue-specific evaluation protocol:

  • Analyze multiple tissues (muscle, fibroblasts, blood cells) from the same patient

  • Compare MT-ATP6 protein levels with tissue-specific heteroplasmy levels

  • Create correlation plots between protein levels and clinical parameters

• Structural impact assessment:

  • Use 2D-BNGE followed by Western blotting with MT-ATP6 antibodies to confirm incorporation of residual MT-ATP6 protein into fully assembled complex V

  • Compare migration patterns between patient and control samples to identify structural abnormalities

• Functional correlation approach:

  • Combine antibody detection with functional measurements:

    • ATP synthesis rates

    • ATP hydrolysis capacity

    • Mitochondrial membrane potential

• Research findings from patient studies:

  • Truncating MT-ATP6 mutations (e.g., m.8782G>A; p.Gly86* and m.8618dup; p.Thr33Hisfs*32) result in:

    • Accumulation of F1 subcomplexes

    • Reduced but detectable levels of fully assembled complex V

    • Decreased steady-state levels of MT-ATP6 protein (~40% reduction)

These methodologies have revealed that even with significant reductions in MT-ATP6 protein, residual complex V assembly occurs, explaining the variable clinical presentation observed in patients. Importantly, MT-ATP6 antibody-based analyses have helped establish that different mutations can lead to distinct assembly defects despite similar clinical presentations, providing insights into disease mechanisms.

What methodological approaches allow correlation of MT-ATP6 mutations with disease phenotypes?

Correlating MT-ATP6 mutations with disease phenotypes requires integrated methodological approaches:

• Heteroplasmy-phenotype correlation methodology:

  • Quantify mutation load across multiple tissues using next-generation sequencing

  • Plot heteroplasmy levels against age of disease onset

  • Stratify by phenotype (e.g., Leigh syndrome vs. NARP)

  • Calculate statistical correlations to quantify relationships

• Tissue-specific threshold determination:

  • Systematically analyze samples from patients with the same mutation but different clinical presentations

  • Determine tissue-specific threshold levels at which biochemical defects appear

  • Establish tissue-specific heteroplasmy thresholds for different phenotypic manifestations

• Protein-function relationship analysis:

  • Measure MT-ATP6 protein levels using calibrated Western blotting

  • Correlate protein abundance with ATP synthesis rates

  • Assess relationship between protein levels and clinical severity metrics

• Published correlation data:

  • Meta-analysis of reported MT-ATP6 cases (n=218) revealed:

    • Significantly higher heteroplasmy load in symptomatic vs. asymptomatic individuals (p=1.6×10^-39)

    • Higher heteroplasmy levels in earlier-onset phenotypes

    • Inverse correlation between heteroplasmy level and age of onset (Pearson coefficient = -0.37, p=1.6E-07)

  • Leigh syndrome patients show significantly higher heteroplasmy than NARP patients (p=0.037)

• Functional phenotyping approach:

  • Utilize patient-derived fibroblasts, transmitochondrial cybrids, and muscle samples

  • Compare biochemical parameters across mutations

  • Establish functional fingerprints for different mutation types

These approaches have demonstrated that while heteroplasmy level is a significant predictor of disease severity, considerable overlap exists between symptomatic and asymptomatic individuals, highlighting the importance of additional factors in determining disease expression.

How can researchers use MT-ATP6 antibodies to evaluate potential therapeutic interventions?

MT-ATP6 antibodies play a crucial role in evaluating therapeutic interventions for mitochondrial diseases through multiple methodological approaches:

• Pre-clinical efficacy assessment protocol:

  • Baseline characterization: Establish MT-ATP6 protein levels and complex V assembly state

  • Post-intervention analysis: Monitor changes in protein expression, stability, and complex assembly

  • Complementary functional measures: Correlate protein changes with ATP synthesis, membrane potential, and cellular respiration

• Gene therapy evaluation methodology:

  • Use Western blotting with MT-ATP6 antibodies to quantify protein expression following gene delivery

  • Assess complex V assembly state using Blue Native PAGE

  • Measure wild-type vs. mutant protein expression in heteroplasmic models

  • Correlate protein expression with functional recovery

• Cell-based therapeutic screening approach:

  • Establish patient-derived cellular models with defined MT-ATP6 mutations

  • Screen compounds for their ability to enhance mutant MT-ATP6 stability or function

  • Use antibody-based high-content screening to quantify changes in protein levels

  • Validate hits with secondary functional assays

• Time-course analysis framework:

  • Monitor MT-ATP6 protein levels at multiple time points following intervention

  • Assess durability of therapeutic effect

  • Compare kinetics of protein restoration with functional recovery

• Mutation-specific considerations:

  • For missense mutations: monitor total protein levels and complex assembly

  • For truncating mutations: assess both wild-type protein levels and presence of truncated forms

  • For mutations affecting stability: focus on protein half-life measurements

Research with mouse models of Leigh syndrome has demonstrated the value of this approach, using MT-ATP6 antibodies to confirm successful expression of functional protein following gene therapy intervention, with corresponding improvements in ATP synthesis and clinical parameters . The ability to detect both mutant and wild-type protein makes antibody-based methods particularly valuable for evaluating heteroplasmy-shifting approaches.

How are new antibody-based technologies advancing MT-ATP6 research?

Emerging antibody-based technologies are transforming MT-ATP6 research through innovative approaches:

• Single-molecule localization microscopy applications:

  • Super-resolution imaging using fluorophore-conjugated MT-ATP6 antibodies (e.g., Alexa Fluor 647/750)

  • Nanoscale visualization of MT-ATP6 distribution within the inner mitochondrial membrane

  • Multi-color imaging to map spatial relationships with other complex V components

• Proximity labeling methodologies:

  • APEX2 or BioID fusion proteins combined with MT-ATP6 antibodies

  • Mapping the dynamic protein interaction network surrounding MT-ATP6

  • Identifying novel regulatory partners and assembly factors

• Advanced antibody engineering approaches:

  • Development of bifunctional antibodies with targeted degradation capabilities

  • Mannose 6-phosphonate derivatives (AMFA) conjugated to antibodies for lysosomal targeting

  • Application of these principles to target pathological MT-ATP6 variants

• Cryo-electron tomography applications:

  • Immunogold labeling with MT-ATP6 antibodies

  • 3D visualization of MT-ATP6 within the native mitochondrial membrane environment

  • Structural analysis of mutation-induced conformational changes

• Single-cell proteomics integration:

  • Combining antibody-based detection with single-cell isolation techniques

  • Analyzing MT-ATP6 expression heterogeneity within tissues

  • Correlating protein levels with single-cell functional parameters

These technologies enable researchers to address previously intractable questions about MT-ATP6 biology and pathology, particularly regarding the spatial organization of ATP synthase, the impact of mutations on protein-protein interactions, and the heterogeneity of expression across different cellular contexts.

What new methodologies combine MT-ATP6 antibodies with functional assays for comprehensive analysis?

Integrative approaches combining MT-ATP6 antibody detection with functional assessments are providing deeper insights into mitochondrial biology:

• Live-cell imaging with functional reporters:

  • Combine immunofluorescence using MT-ATP6 antibodies with:

    • Potential-sensitive dyes (TMRM, JC-1) for membrane potential

    • pH-sensitive probes for proton gradient measurement

    • ATP sensors (e.g., ATeam) for local ATP production

  • Correlate MT-ATP6 localization with functional parameters at the single-cell level

• High-content screening platforms:

  • Automated image analysis of MT-ATP6 immunostaining

  • Simultaneous quantification of multiple functional parameters

  • Machine learning algorithms to identify subtle phenotypic changes

  • Application to drug screening or genetic modifier identification

• Flow cytometry-based multiparameter analysis:

  • MT-ATP6 antibody staining combined with functional mitochondrial dyes

  • Single-cell correlation between protein levels and function

  • Sorting of cell populations based on combined parameters for downstream analysis

• Real-time functional monitoring coupled with endpoint antibody analysis:

  • Measure oxygen consumption, ATP production, or membrane potential in living cells

  • Follow with fixation and MT-ATP6 immunostaining

  • Correlate functional data with protein expression/localization

• Microfluidic approaches:

  • Single-cell isolation and analysis

  • Combined functional testing and antibody-based protein quantification

  • Temporal analysis of protein expression and functional changes

These integrated approaches have revealed that MT-ATP6 mutations can lead to diverse biochemical consequences, including reduced ATP synthesis rate, preserved ATP hydrolysis capacity, and abnormally increased mitochondrial membrane potential, though no single biochemical feature is universally observed across different mutations . This highlights the importance of comprehensive multiparameter analysis in characterizing mitochondrial diseases.

How can researchers leverage MT-ATP6 antibodies for studying the relationship between mitochondrial structure and function?

MT-ATP6 antibodies provide powerful tools for investigating the structural basis of mitochondrial function:

• Super-resolution microscopy applications:

  • STORM or PALM imaging with MT-ATP6 antibodies to visualize ATP synthase distribution

  • Analysis of cristae membrane organization and ATP synthase dimer rows

  • Correlation of structural changes with functional deficits in disease models

• Electron microscopy methodologies:

  • Immunogold labeling for precise localization of MT-ATP6 within the ATP synthase complex

  • Correlative light and electron microscopy (CLEM) to link protein localization with ultrastructural features

  • Tomographic reconstruction of ATP synthase organization in native membranes

• Structure-function correlation approaches:

  • Combine structural imaging with patch-clamp recording of mitochondrial membranes

  • Correlate MT-ATP6 distribution with local proton conductance

  • Map functional defects to structural abnormalities

• In situ proximity labeling:

  • Use MT-ATP6 antibodies to identify interaction partners in intact mitochondria

  • Map the spatial organization of protein complexes within the inner membrane

  • Identify structural changes associated with pathogenic mutations

• Advanced tissue preparation methods:

  • Expansion microscopy with MT-ATP6 immunostaining for enhanced resolution

  • Tissue clearing techniques combined with whole-mount immunolabeling

  • 3D reconstruction of mitochondrial networks with ATP synthase distribution